Estrella Immunopharma, Inc. SEC filings ESLAW

Estrella Immunopharma, Inc. has 258 filings in SEC EDGAR's recent list, going back to Feb 19, 2021. Its latest annual report, Form 10-K, was filed on Mar 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
10-Q Quarterly report May 18, 2026 Mar 31, 2026
10-Q Quarterly report Nov 12, 2025 Sep 30, 2025
10-Q Quarterly report Aug 12, 2025 Jun 30, 2025
10-Q Quarterly report May 14, 2025 Mar 31, 2025
10-Q Quarterly report Nov 14, 2024 Sep 30, 2024
10-Q Quarterly report May 15, 2024 Mar 31, 2024
10-Q Quarterly report Feb 14, 2024 Dec 31, 2023
10-Q Quarterly report Nov 20, 2023 Sep 30, 2023
10-Q Quarterly report Aug 1, 2023 Jun 30, 2023
10-Q Quarterly report May 18, 2023 Mar 31, 2023
10-Q Quarterly report Nov 14, 2022 Sep 30, 2022
10-Q Quarterly report Aug 8, 2022 Jun 30, 2022
10-Q Quarterly report May 16, 2022 Mar 31, 2022
10-Q Quarterly report Nov 10, 2021 Sep 30, 2021

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ESLA (Nasdaq), ESLAW (Nasdaq)
Fiscal year ends
December 31
Headquarters
Emeryville, CA
SEC filer status
, Emerging growth company
SEC CIK
1844417
Former names
TradeUP Acquisition Corp. (until Sep 20, 2023)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.